Share Email Print
cover

Proceedings Paper

Flow cytometry systems for drug discovery and development
Author(s): John T. Ransom; Bruce S. Edwards; Frederick W. Kuckuck III; Alex Okun; David K. Mattox; Eric R. Prossnitz; Larry A. Sklar
Format Member Price Non-Member Price
PDF $17.00 $21.00

Paper Abstract

HT-PS is a fluidics-based pharmacology platform that uses viable cells and test compounds to rapidly identify active compounds and immediately determine their potency and specificity. Axiom employs this proprietary flow-through fluidics system coupled to a flow cytometer (FCM) as a detection system. Integration of FCM was enabled through a Plug-Flow Coupler (PFC) device that allows mixtures of cells and test compounds to be delivered to the FCM as discrete plugs of samples under positive air pressure. An FCM detector provides the advantages of multi parametric measurements and multiplexed, single cell analyses. Assays that combine two or more compatible, fluorescent bioresponse indicators simultaneously, such as measurements of intracellular pH and Ca2+, are possible. Alternatively, measurements of one or more bioresponses can be performed on several distinct cell populations individually stained with uniquely addressable fluorescent chromophores. These formats enable multiple experiments on a single sample and provide high content information thereby greatly increasing decision-making power regarding the activity, potency and selectivity of a test compound. Development of significant data with several hundred cells enables reduction in all requisite sample volumes. The PFC enables FCM sample analysis rates of at least 10 samples/minute. The data will illustrate HT-PS/PFC/FCM utility in the drug discovery arena.

Paper Details

Date Published: 27 April 2000
PDF: 11 pages
Proc. SPIE 3921, Optical Diagnostics of Living Cells III, (27 April 2000); doi: 10.1117/12.384201
Show Author Affiliations
John T. Ransom, Axiom Biotechnologies, Inc. (United States)
Bruce S. Edwards, Univ. of New Mexico Cancer Research and Treatment Ctr. (United States)
Frederick W. Kuckuck III, Univ. of New Mexico Cancer Research and Treatment Ctr. (United States)
Alex Okun, Axiom Biotechnologies, Inc. (United States)
David K. Mattox, Axiom Biotechnologies, Inc. (United States)
Eric R. Prossnitz, Univ. of New Mexico Cancer Research and Treatment Ctr. (United States)
Larry A. Sklar, Univ. of New Mexico Cancer Research and Treatment Ctr. (United States)


Published in SPIE Proceedings Vol. 3921:
Optical Diagnostics of Living Cells III
Daniel L. Farkas; Daniel L. Farkas; Robert C. Leif, Editor(s)

© SPIE. Terms of Use
Back to Top